Hakon Leffler
31 – 40 of 167
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
Structure-Guided Design of d -Galactal Derivatives with High Affinity and Selectivity for the Galectin-8 N-Terminal Domain
(
- Contribution to journal › Article
-
Mark
Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis
(
- Contribution to journal › Article
- 2020
-
Mark
Epimers Switch Galectin-9 Domain Selectivity : 3 N-Aryl Galactosides Bind the C-Terminal and Gulosides Bind the N-Terminal
(
- Contribution to journal › Article
-
Mark
In Vivo Veritas : 18F-Radiolabeled Glycomimetics Allow Insights into the Pharmacological Fate of Galectin-3 Inhibitors
(
- Contribution to journal › Article
- 2019
-
Mark
Substituted polyfluoroaryl interactions with an arginine side chain in galectin-3 are governed by steric-, desolvation and electronic conjugation effects
(
- Contribution to journal › Article
-
Mark
Extracellular and intracellular small-molecule galectin-3 inhibitors
(
- Contribution to journal › Article
-
Mark
Human trophoblast requires galectin-3 for cell migration and invasion
(
- Contribution to journal › Article
-
Mark
Interplay between Conformational Entropy and Solvation Entropy in Protein-Ligand Binding
(
- Contribution to journal › Article
-
Mark
An orally active galectin-3 antagonist inhibits lung adenocarcinoma growth and augments response to PD-L1 blockade
(
- Contribution to journal › Article
-
Mark
Galectin-3, a novel endogenous TREM2 ligand, detrimentally regulates inflammatory response in Alzheimer’s disease
(
- Contribution to journal › Article